Cancer Family
Bone Marrow Neoplasm
CI-CAN-00000093Explore in graph →
Non-malignant1,033 active trials28 approved drugs633 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000093Explore in graph →
Clinical trials
4,617 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00530218 | Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant | completed | Phase 2 | 61 | City of Hope Medical CenterOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT01163201 | T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 2, 2017 |
| clinicaltrials |
| NCT01639456 | CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete Remission | withdrawn | Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT01677949 | Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia | withdrawn | Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT00365287 | Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer | completed | Phase 1 / Phase 2 | 148 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Nov 29, 2017 | clinicaltrials |
| NCT03356080 | DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess | unknown | Phase 2 | 50 | Shanghai Tong Ren HospitalOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00186628 | Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD | completed | Phase 2 | 36 | Stanford UniversityOTHER | 1 | Nov 28, 2017 | clinicaltrials |
| NCT00822094 | Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML) | completed | Phase 2 | 126 | Jazz PharmaceuticalsINDUSTRY | 4 | Nov 24, 2017 | clinicaltrials |
| NCT03108911 | Gluten Free Diet in Diminishing Side Effects Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy | terminated | Phase 2 | 1 | Rutgers, The State University of New JerseyOTHER | 1 | Nov 17, 2017 | clinicaltrials |
| NCT02433483 | Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients | terminated | Phase 2 | 4 | St. Jude Children's Research HospitalOTHER | 1 | Nov 1, 2017 | clinicaltrials |
| NCT00101140 | Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission | withdrawn | Phase 2 | 0 | Eastern Cooperative Oncology GroupNETWORK | 0 | Oct 19, 2017 | clinicaltrials |
| NCT01101880 | Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm | completed | Phase 2 | 50 | University of WashingtonOTHER | 1 | Oct 19, 2017 | clinicaltrials |
| NCT00309907 | Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant | completed | Phase 2 | 39 | Children's Oncology GroupNETWORK | 1 | Sep 29, 2017 | clinicaltrials |
| NCT00301834 | Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders | completed | Phase 2 | 35 | University of California, San FranciscoOTHER | 1 | Sep 28, 2017 | clinicaltrials |
| NCT00245037 | Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer(Bu Flu TBI) | completed | Phase 1 / Phase 2 | 147 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 27, 2017 | clinicaltrials |
| NCT00281879 | Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer | terminated | Phase 2 | 200 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 27, 2017 | clinicaltrials |
| NCT02544438 | Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia(BSTPHASE1-01) | completed | Phase 1 / Phase 2 | 20 | BioSight Ltd.INDUSTRY | 1 | Sep 27, 2017 | clinicaltrials |
| NCT00852566 | Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia(NordCML006) | completed | Phase 2 | 46 | Norwegian University of Science and TechnologyOTHER | 3 | Sep 25, 2017 | clinicaltrials |
| NCT00949364 | Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage | completed | Phase 2 | 103 | University of UlmOTHER | 1 | Sep 25, 2017 | clinicaltrials |
| NCT00151242 | Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 2 / Phase 3 | 920 | University of UlmOTHER | 2 | Sep 20, 2017 | clinicaltrials |
| NCT00005940 | Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First Remission | completed | Phase 2 | 18 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 30, 2017 | clinicaltrials |
| NCT01947322 | Haploidentical NK-cell Infusion in Acute Myeloid Leukemia(NK) | completed | Phase 1 / Phase 2 | 10 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Aug 29, 2017 | clinicaltrials |
| NCT03256071 | Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCT | unknown | Phase 2 / Phase 3 | 90 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 21, 2017 | clinicaltrials |
| NCT01141725 | Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS | completed | Phase 1 / Phase 2 | 39 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 18, 2017 | clinicaltrials |
| NCT01606579 | Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies | completed | Phase 1 / Phase 2 | 49 | Prism Pharma Co., Ltd.INDUSTRY | 1 | Aug 17, 2017 | clinicaltrials |
| NCT00702403 | Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML | completed | Phase 1 / Phase 2 | 40 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 10, 2017 | clinicaltrials |
| NCT03241199 | The Efficacy and Safety of Induction-Maintenance Protocol for Patients With Chronic Myelogenous Leukaemia | unknown | Phase 2 | 15 | The University of Hong KongOTHER | 1 | Aug 8, 2017 | clinicaltrials |
| NCT01349972 | Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 2 | 172 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2017 | clinicaltrials |
| NCT02899286 | Efficacy and Safety Study of Recombinant Human Arginase 1 in Patients With Relapsed or Refractory Acute Myeloid Leukemia | unknown | Phase 2 | 25 | Bio-Cancer Treatment International LimitedINDUSTRY | 1 | Jul 28, 2017 | clinicaltrials |
| NCT00261846 | Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias | completed | Phase 2 | 571 | PfizerINDUSTRY | 27 | Jul 27, 2017 | clinicaltrials |
| NCT00462605 | MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Jul 18, 2017 | clinicaltrials |
| NCT00448357 | Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen(LCCC0510) | completed | Phase 1 / Phase 2 | 54 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jul 17, 2017 | clinicaltrials |
| NCT01643668 | Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation | completed | Phase 2 | 34 | Massachusetts General HospitalOTHER | 1 | Jul 13, 2017 | clinicaltrials |
| NCT00839982 | Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS | completed | Phase 1 / Phase 2 | 35 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 11, 2017 | clinicaltrials |
| NCT00079313 | Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia | completed | Phase 2 | 7 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01342887 | Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 6 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 2, 2017 | clinicaltrials |
| NCT02802267 | Efficacy Study of Inecalcitol With Decitabine in Acute Myeloid Leukemia Patients Unfit for Standard Chemotherapy | unknown | Phase 2 | 110 | Hybrigenics CorporationINDUSTRY | 2 | Jul 2, 2017 | clinicaltrials |
| NCT03205267 | Phase II Study Testing the Tolerability and the Efficacy of Bosutinib in Chronic Phase CML Patients(BODO) | unknown | Phase 2 | 127 | University of BonnOTHER | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01520558 | CNDO-109-AANK for AML in First Complete Remission (CR1) | unknown | Phase 1 / Phase 2 | 12 | Coronado Biosciences, Inc.INDUSTRY | 1 | Jun 29, 2017 | clinicaltrials |
| NCT00607997 | Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia | completed | Phase 2 | 113 | Sunesis PharmaceuticalsINDUSTRY | 1 | Jun 28, 2017 | clinicaltrials |
| NCT00691015 | Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant | completed | Phase 2 | 48 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jun 28, 2017 | clinicaltrials |
| NCT00854945 | Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML | completed | Phase 1 / Phase 2 | 36 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT01167166 | Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL) | completed | Phase 1 / Phase 2 | 30 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT00538980 | Dasatinib in Polycythemia Vera | terminated | Phase 2 | 10 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 20, 2017 | clinicaltrials |
| NCT00145626 | HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies | completed | Phase 2 | 40 | St. Jude Children's Research HospitalOTHER | 1 | Jun 19, 2017 | clinicaltrials |
| NCT00719849 | Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease | terminated | Phase 2 | 13 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT00744536 | Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS(REMMYDYS) | completed | Phase 2 | 20 | Sunnybrook Health Sciences CentreOTHER | 1 | Jun 9, 2017 | clinicaltrials |
| NCT00687323 | Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052)(TALL) | completed | Phase 2 | 47 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 7, 2017 | clinicaltrials |
Data updated 24 days agoSource updated Dec 2, 2017source: clinicaltrials